Breaking News

Tweet TWEET

Orion Oyj : Notice to the Annual General Meeting of Orion Corporation

    Orion Oyj : Notice to the Annual General Meeting of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE5FEBRUARY 2013 at 12.15EET

The Board of Directors of Orion Corporation has decided today to convene the
Annual General Meeting of the Shareholders of Orion Corporation on 19 March
2013. The Notice to the Meeting will be published in Finnish in the Helsingin
Sanomat newspaper on Wednesday, 6 February 2013, with the following contents:

          Notice to the Annual General Meeting of Orion Corporation

Notice is given to the shareholders of Orion Corporation to the Annual General
Meeting to be held
on Tuesday 19 March 2013 at 2.00 p.m. at the Helsinki Fair Centre, address:
Messuaukio 1, Helsinki. The reception of the participants and the distribution
of the voting tickets will start at 12.30.
Coffee will be served after the meeting.

A. Agenda of the Meeting, in the order of handling

1. Opening of the Meeting

2. Matters of order for the Meeting

3. Election of the person to confirm the minutes and the persons to
verify the counting of votes

4. Recording the legal convening of the Meeting and quorum

5. Recording the attendance at the Meeting and the list of votes

6. Presentation of the Financial Statements 2012, the report of the
Board of Directors and the Auditor's report

- Review by the President and CEO

7. Adoption of the Financial Statements

8. Decision on the use of the profits shown on the Balance Sheet
and the payment of the dividend

The Board of Directors proposes that a dividend of EUR 1.30 per share be paid
on the basis of the Balance Sheet confirmed for the financial year that ended
on 31 December 2012. According to the proposal, the dividend is paid to Orion
Corporation shareholders entered in the Company's register of shareholders
maintained by Euroclear Finland Ltd on the record date, 22 March 2013. The
date of the dividend payment is 4 April 2013.

Shareholders having not registered their shares in the book-entry system by
the record date for dividend payment shall receive the dividend payment only
after registration of their shares in the system.

9. Decision on the discharge of the members of the Board of
Directors and the President and CEO from liability

10. Decision on the remuneration of the members of the Board of
Directors

The Company's Nomination Committee has announced as its recommendation that
the following remunerations be paid to the Board of Directors:

As an annual fee, the Chairman would receive EUR 76,000, the Vice Chairman
would receive EUR 51,000 and the other members would receive EUR 38,000 each.
As a fee for each meeting attended, the Chairman would receive EUR 1,200, the
Vice Chairman would receive EUR 900 and the other members would receive EUR
600 each. The travel expenses of the Board members would be paid in accordance
with previously adopted practice. The aforementioned fees would also be paid
to the Chairmen and to the members of the committees established by the Board,
for each committee meeting attended.

Of the annual fee, 60% would be paid in cash and 40% in Orion Corporation
B-shares, which would be acquired to the members during 25-28 March 2013 from
the stock exchange in amounts corresponding to EUR 30,400 for the Chairman,
EUR 20,400 for the Vice Chairman and EUR 15,200 for each of the other members.
The part of the annual fee that is to be paid in cash corresponds to the
approximate sum necessary for the payment of the income taxes on the fees and
would be paid no later than 30 April 2013. The annual fees shall encompass the
full term of office of the Board of Directors.

The Nomination Committee has not given its recommendation for the
remunerations to the Board of Directors, but the matter will be proposed by a
shareholder at the Annual General Meeting.

11. Decision on the number of members of the Board of Directors

In accordance with the recommendation by the Company's Nomination Committee,
the Board of Directors proposes to the Annual General Meeting that the number
of the members of the Board of Directors be six.

12. Election of the members and the Chairman of the Board of
Directors

In accordance with the recommendation by the Nomination Committee, the Board
of Directors proposes to the Annual General Meeting that the present Board
members, Sirpa Jalkanen, Eero Karvonen, Timo Maasilta, Hannu Syrjänen, Heikki
Westerlund and Jukka Ylppö be re-elected for the next term of office.

The current Chairman of the Board Hannu Syrjänen would be re-elected as
Chairman.

13. Decision on the remuneration of the Auditor

In accordance with the recommendation by the Board's Audit Committee, the
Board of Directors proposes to the Annual General Meeting that the
remunerations to the Auditor be paid on the basis of invoicing approved by the
Company.

14. Election of the Auditor

In accordance with the recommendation by the Board's Audit Committee, the
Board of Directors proposes to the Annual General Meeting that
PricewaterhouseCoopers Oy, authorised public accountants, be elected as the
Company's auditor.

15. Authorising the Board of Directors to decide to acquire the
Company's own shares

The Board of Directors proposes to the Annual General Meeting that the Board
be authorised to decide on the acquisition of the Company's own shares on the
following terms and conditions:

Maximum amount of shares to be acquired

On the basis of the authorisation, the Board of Directors shall be entitled to
decide on the acquisition of no more than 500,000 B-shares of Orion
Corporation.

Consideration to be paid for the shares

The own shares shall be acquired at the price of the acquisition moment quoted
at trading on regulated market organised by NASDAQ OMX Helsinki Ltd ("Stock
Exchange"), using funds in the Company's distributable equity.

Targeted acquisition

The own shares shall be acquired through trading on regulated market organised
by the Stock Exchange in a proportion not corresponding to the shareholders'
holdings. The shares shall be acquired and paid for in accordance with the
rules of the Stock Exchange and Euroclear Finland Ltd.

 Holding, invalidation and conveyance of the shares

The shares acquired can be kept, invalidated, or further conveyed by the
Company.

The shares can be acquired for the purpose of developing the capital structure
of the Company, for using them for financing possible corporate acquisitions
or other business arrangements of the Company, for financing capital
expenditure, as part of the Company's incentive system, or otherwise conveying
or invalidating them.

Other terms and validity

The Board of Directors shall decide on other matters related to the
acquisition of own shares.

The authorisation to acquire own shares shall be valid 18 months from the
decision of the Annual General Meeting of the Shareholders.

16. Authorising the Board of Directors to decide on a share issue

The Board of Directors proposes to the Annual General Meeting that the Board
of Directors be authorised to decide on a share issue in which the Company's
own shares held by the Company can be conveyed on the following terms and
conditions:

 Maximum amount of shares to be conveyed

On the basis of the authorisation, the Board of Directors shall be entitled to
decide on the conveyance of no more than 600,000 own B-shares held by the
Company.

Conveyance against and without payment

The own shares held by the Company can be conveyed either against or without
payment.

Shareholders' pre-emptive rights and targeted issue

The own shares held by the Company can be conveyed

- by selling them through trading on regulated market organised by
NASDAQ OMX Helsinki Ltd ("Stock Exchange");
- in a targeted issue to the Company's shareholders in the
proportion corresponding to their holdings at the moment of the conveyance
regardless of whether they own A- or B-shares; or
- in a targeted issue, deviating from the shareholders' pre-emptive
rights, if there is a weighty financial reason, such as the development of the
capital structure of the Company, using the shares for financing possible
corporate acquisitions or other business arrangements of the Company,
financing capital expenditure or as part of the Company's incentive system.
The targeted share issue can be without payment only if there is an especially
weighty financial reason in view of the Company and the benefit of all its
shareholders.

 Subscription price in the Balance Sheet

The amounts paid for own shares conveyed shall be recorded in a fund in the
distributable equity.

Other terms and validity

The Board of Directors shall decide on other matters related to the conveyance
of own shares.

The authorisation to convey own shares shall be valid five years from the
decision of the Annual General Meeting of the Shareholders.

This decision cancels the share issue authorisation confirmed by the Annual
General Meeting of Orion Corporation on 24 March 2010, for the part which has
not yet been exercised. 

17. Closing the Meeting

B. Documents of the Annual General Meeting

The unofficial English versions of the proposals of the Board of Directors and
of the recommendation of the Nomination Committee as well as this Notice to
the Annual General Meeting are available on the website of Orion Corporation,
at www.orion.fi. The Financial Statement documents of Orion Corporation, which
include the Financial Statements, the Report of the Board of Directors and the
Auditor's Report, will be available on the above-mentioned website no later
than 26 February 2013. The proposals of the Board of Directors and the
Financial Statement documents will also be available at the Annual General
Meeting.

C. Instructions for the participants in the Annual General Meeting

1. The right to participate and registration

Shareholders being registered in the Company's register of shareholders,
maintained by Euroclear Finland Ltd, on 7 March 2013 have the right to attend
the Annual General Meeting. A shareholder, whose shares are registered on
his/her personal Finnish book-entry account, is registered in the Company's
register of shareholders.

A shareholder, who intends to participate in the Annual General Meeting, shall
register for the Meeting by giving a prior notice of participation to the
Company no later than 14March2013 at 10.00a.m. Finnish time. The notice can
be given in either of the following ways:

a.Through Internet, at www.orion.fi
b.By telephone to +358104265252 (Monday-Friday 8:00 a.m.-6:00 p.m.)
c.By letter to Orion Corporation, Treasury, P.O.Box65, FI-02101Espoo,
    Finland.

In the registration, a shareholder shall notify his/her name, personal
identification code or the company code, address, phone number and the name
and the personal identification of a possible assistant or proxy
representative. The personal registering details submitted to Orion
Corporation will only be used in connection with the Annual General Meeting
and necessary registrations relating to it.

2. Holders of nominee registered shares

A holder of nominee registered shares has the right to participate in the
Annual General Meeting on the basis of those shares as would entitle him/her
to be registered in the shareholder register maintained by Euroclear Finland
Ltd on 7 March 2013. Additionally, the holder of those shares is requested to
be temporarily entered in the shareholder register maintained by Euroclear
Finland Ltd no later than 14 March 2013 at 10:00 a.m. Finnish time. For
nominee registered shares, this constitutes due registration for the Annual
General Meeting.

A holder of nominee registered shares is advised to request early enough the
necessary instructions concerning the temporary registration in the Company's
register of shareholders, the issuing of proxy documents and the registration
for the Annual General Meeting from his/her custodian bank. The holder of
nominee registered shares who aims to participate in the Annual General
Meeting, must be temporarily entered by the custodian bank in the Company's
register of shareholders no later than the above-mentioned time.

3. Proxy representation and powers of attorney

A shareholder may participate in the Annual General Meeting and exercise
his/her rights at the Meeting by way of proxy representation. A proxy
representative shall present a dated proxy document or otherwise in a reliable
manner demonstrate his/her right to represent the shareholder at the Meeting.
If a shareholder attends the Meeting by way of several proxy holders
representing the shareholder with shares entered in different security
accounts, the shares represented by each proxy holder must be identified when
registering for the Annual General Meeting.

Possible proxies are requested to be delivered in originals to Orion
Corporation, Treasury, P.O.Box 65, FI-02101 Espoo, Finland, before the end of
the registration period.

4. Other information

Pursuant to chapter 5, section 25 of the Companies Act, a shareholder who is
present at the Annual General Meeting has the right to request information on
the matters dealt with at the Meeting.

On 5 February 2013, the date of the Notice to the Annual General Meeting, the
total number of shares in Orion Corporation is 141,257,828, of which
43,235,318 are Class A shares and 98,022,510 are Class B shares. The total
number of votes is 962,728,870, of which Class A shares account for
864,706,360 votes and Class B shares for 98,022,510 votes.

Espoo, 5 February 2013

Orion Corporation
Board of Directors

Orion Corporation

Timo Lappalainen     Olli Huotari
President and CEO    Senior Vice President, Corporate
Functions

Contact persons:

Timo Lappalainen, President and CEO, phone +35810426 3692
Olli Huotari, Senior VP, Corporate Functions, Secretary of the Board of
Directors, phone +358509663054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion Corporation

Timo Lappalainen  Olli Huotari
President and CEO SVP, Corporate Functions 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. Pharmaceutical R&D focuses on central nervous
system drugs, oncology and critical care drugs, and Easyhaler^® pulmonary
drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX
Helsinki.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Orion Oyj via Thomson Reuters ONE
HUG#1675530
 
Press spacebar to pause and continue. Press esc to stop.